Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phio Pharmaceuticals Corp. filings document material events for a clinical-stage siRNA biopharmaceutical company developing INTASYL® gene-silencing therapeutics in immuno-oncology. Recent 8-K disclosures report quarterly and year-end financial results, PH-762 clinical and safety updates, tumor-response data, and development activities for skin cancer indications including cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
The company's regulatory record also covers material agreements and capital-structure matters, including a cGMP drug-product manufacturing services agreement for PH-762 clinical supply and an at-the-market common-stock offering under a shelf registration statement. Governance disclosures include executive employment-agreement amendments and related compensatory arrangements.
Phio Pharmaceuticals Corp. (PHIO) director Ronald Todd Plott reported an open-market or private purchase of company stock. On 2026-08-19, he bought 15,000 shares of common stock at $1.14 per share. Following this transaction, he directly holds 15,000 shares of Phio Pharmaceuticals common stock.
Phio Pharmaceuticals Corp. (PHIO) reported that Chairman, President and CEO Robert J. Bitterman purchased 10,000 shares of common stock on August 18, 2026, in an open-market or private transaction at $1.06 per share. Following this transaction, he directly holds 431,421 shares, which include shares underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. plans a virtual 2026 annual stockholder meeting on September 28, 2026 to elect six directors, ratify Grant Thornton LLP as independent auditor for 2026, and approve an amendment to the 2020 Long Term Incentive Plan.
The equity plan amendment would add 1,500,000 shares, bringing total shares authorized under the plan to 2,452,017, about 21.1% of the 11,617,250 common shares outstanding as of August 4, 2026. The Board cites a three‑year average equity burn rate of 6.6% and projects the added capacity could fund roughly two years of equity grants.
The proxy outlines Board structure, committee independence, director and executive compensation (including 2025 RSU grants and incentive bonuses), and an Incentive Compensation Recovery Policy. Prior audit reports from BDO for 2023 and 2024 contained an explanatory paragraph about substantial doubt regarding Phio’s ability to continue as a going concern.
Phio Pharmaceuticals Corp. reported financial results for the quarter ended June 30, 2026 and provided an update on its lead INTASYL®-based candidate PH-762. Research and development expenses for the quarter were $3.1 million, an increase of $2.0 million or 187%, driven mainly by nonclinical toxicology and CMC work on PH-762. General and administrative expenses were $1.2 million, slightly lower than the prior-year quarter, and quarterly net loss was $4.1 million compared with $2.2 million a year earlier.
As of June 30, 2026, Phio held $13.0 million in cash and cash equivalents versus $21.0 million at December 31, 2025, and management expects existing cash to fund planned operations into the second half of 2027. In April 2026 the company established an at the market equity offering program of up to $6.36 million. PH-762 completed a 22-patient Phase 1b intratumoral trial in skin cancers; final documentation is being prepared for FDA submission, and Phio intends to request an FDA meeting in the third quarter of 2026 to discuss next clinical steps. The company also initiated commercial-scale API production and a long-term non-clinical toxicology study expected to complete by year end, reported multiple new patent allowances in the United States, Canada and Japan, and appointed dermatologist and former FDA advisory committee member Dr. R. Todd Plott to its board.
Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company developing cancer immunotherapies based on its proprietary INTASYL self-delivering siRNA platform. Lead program PH-762 targets PD-1 to enhance T-cell killing of tumors, with a second program, PH-894, targeting BRD4; the PH-894 IND has been deferred while PH-762 is prioritized.
In a completed U.S. Phase 1b trial of intratumoral PH-762 in cutaneous squamous cell carcinoma and other skin cancers, 13 of 20 cSCC patients had pathologic responses, supporting a 65% overall response rate, including 9 complete responses, with PH-762 reported as well tolerated and without dose-limiting toxicities. A pivotal GLP toxicology study and new cGMP drug substance and product manufacturing are underway, and an FDA meeting request is targeted for the third quarter of 2026 to discuss next-step development.
Phio reported no product revenue and an increased focus on development spending. For the quarter ended June 30, 2026, research and development expenses were $3,082 (thousands) and net loss was $4,138 (thousands); for the six-month period, net loss was $8,141 (thousands). Cash and cash equivalents were $12,996 (thousands) at June 30, 2026, versus $21,031 (thousands) at year-end 2025. The company believes this cash, together with prior 2025 financings, will fund planned obligations for at least 12 months, and it has established an at-the-market program permitting sales of up to $6,360,000 of common stock, with no shares sold to date.
Phio Pharmaceuticals Corp. director Ronald Todd Plott filed an initial beneficial ownership report as a director. The report lists no buy, sell, gift, exercise, or other transactions and shows no reportable holdings of Phio Pharmaceuticals securities in this filing.
Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company, expanded its Board of Directors to six members effective July 20, 2026 and appointed R. Todd Plott, M.D., a board-certified dermatologist, as director until the 2026 annual meeting and as a member of the Governance Committee.
Dr. Plott brings more than 30 years of experience in dermatologic care, research and clinical trials, including service on the FDA Dermatologic and Ophthalmic Drug Advisory Committee from 2016 to 2021. He will enter into Phio’s standard indemnification agreement and receive standard non-employee director compensation, with no related-party arrangements reported.
The company reiterates its focus on its proprietary INTASYL siRNA gene-silencing platform and lead INTASYL compound PH-762, evaluated in a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma as a potential non-surgical skin cancer treatment.
Phio Pharmaceuticals Corp. Chairman, President and CEO Robert J. Bitterman reported an open-market purchase of common stock. On June 26, 2026, he bought 10,000 shares at $0.99 per share. Following this transaction, he directly owns 421,421 shares, which include shares underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. reported a net loss of $4.0M for the quarter ended March 31, 2026, wider than the prior-year loss of $1.8M, as it ramped spending on its lead cancer drug PH-762.
Research and development expenses rose to $2.8M from $0.9M, driven mainly by nonclinical, clinical and manufacturing work on PH-762. General and administrative costs increased to $1.4M from $1.0M, reflecting higher stock-based compensation, bonuses and professional fees.
Cash and cash equivalents were $17.0M at quarter-end, down from $21.0M at December 31, 2025. Management believes this, along with proceeds from 2025 financings, will fund operations for at least 12 months. The company also put in place a new at-the-market equity program allowing sales of up to $6.36M of common stock to support PH-762’s expected Phase 2b/3 trial and general working capital.